Astera Labs, Inc. (ALAB)

NASDAQInformation TechnologySemiconductorsSnapshot 2026-10-23

$257.16-0.26%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge Astera Labs, Inc.’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

-0.0%

+10% or more+5%0%−5%−10% or less

6.49 → 6.49 EPS · FY ending Dec 31, 2027 · 15 analysts

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

Change in the same fiscal period’s mean EPS estimate from Sep 24, 2026 to Oct 24, 2026: (new ÷ prior − 1). Contributor count changed from 15 to 15; this is not the number of analysts revising. Source: FMP consensus snapshots. The ±10% axis is a display range.

Measure / period	Management expectations	Analyst expectations
FY 2026 · Q3
Revenue	$540M–$560M	—
Gross margin	About 72%GAAP About 72%non-GAAP	—
Operating expenses	$156M–$160Mnon-GAAP $232M–$236MGAAP	—
FY 2026 · Q4
Revenue	—	656.29M
EPS	—	1.417
FY 2026 · Annual
Revenue	—	1.91B
EPS	—	3.994
FY 2027 · Annual
Revenue	—	3.08B
EPS	—	6.485

What the Thesis Depends On

4 published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
EPS between $0.44 and $0.46 in 2026-Q2	A primary condition in Astera Labs, Inc.'s published investment case. The stated target is $0.44-$0.46.	Broken	EPS falls below $0.44 in 2026-Q2	Diluted EPS: $0.83 per share FY2026-Q2; GAAP. Published target: $0.44-$0.46. The target does not explicitly identify fiscal versus calendar quarters. Source published Aug 4, 20260.83 USD/share · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: 7d2b6c99-8e45-4f94-bc6b-3bfcbe1431a4. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
GAAP gross margin of 73% in 2026-Q2	It targets $355M-$365M revenue and 73% gross margin in 2026-Q2.	Broken	Gross margin falls below 70% in 2026-Q2	Gross margin: 73.28% FY2026-Q2; GAAP. Published target: 73%. The target does not explicitly identify fiscal versus calendar quarters. Source published Aug 4, 202673.284149 percent · calculatedSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: 7d2b6c99-8e45-4f94-bc6b-3bfcbe1431a4. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Successful adoption of Scorpio network switch products	New Scorpio switching products support growth.	Intact	Failure to gain market traction or revenue from Scorpio products	Qualitative adoption confirmed News confirms Scorpio X-Series 320 launch and positioning as next AI growth engine, supporting the adoption thesis. Context reviewed through Oct 23, 2026Last status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Revenue between $355M and $365M in 2026-Q2	A primary condition in Astera Labs, Inc.'s published investment case. The stated target is $355M-$365M.	Broken	Revenue falls below $355M in 2026-Q2	Revenue: $392.4M FY2026-Q2; GAAP. Published target: $355M-$365M. The target does not explicitly identify fiscal versus calendar quarters. Source published Aug 4, 2026392,400,000 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: 7d2b6c99-8e45-4f94-bc6b-3bfcbe1431a4. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS$6.49

$4.53 → $6.49 · observed estimates

FY2027 revenue$3.08B

$2.24B → $3.08B · observed estimates

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	$4.53	$2,235,197,230	22 / 24
2026-07-25	$4.53	$2,235,197,230	22 / 24
2026-07-26	$4.53	$2,235,197,230	22 / 24
2026-07-27	$4.53	$2,235,197,230	22 / 24
2026-07-28	$4.53	$2,235,197,230	22 / 24
2026-07-29	$4.53	$2,235,197,230	22 / 24
2026-07-30	$4.53	$2,235,197,230	22 / 24
2026-07-31	$4.71	$2,262,744,991	14 / 18
2026-08-01	$4.56	$2,243,809,410	22 / 24
2026-08-02	$4.63	$2,260,771,910	22 / 24
2026-08-03	$4.63	$2,260,771,910	22 / 24
2026-08-04	$4.63	$2,260,771,910	22 / 24
2026-08-05	$4.69	$2,290,348,660	22 / 24
2026-08-06	$4.69	$2,290,348,660	22 / 24
2026-08-07	$6.35	$2,960,708,747	15 / 18
2026-08-08	$6.26	$2,936,724,210	23 / 24
2026-08-09	$6.26	$2,936,724,210	23 / 24
2026-08-10	$6.26	$2,936,724,210	23 / 24
2026-08-11	$6.26	$2,936,724,210	23 / 24
2026-08-12	$6.39	$2,972,720,400	23 / 24
2026-08-13	$6.39	$2,972,720,400	23 / 24
2026-08-14	$6.35	$2,960,708,747	15 / 18
2026-08-15	$6.35	$2,960,708,747	15 / 18
2026-08-16	$6.35	$2,960,708,747	15 / 18
2026-08-17	$6.35	$2,960,708,747	15 / 18
2026-08-18	$6.35	$2,960,708,747	15 / 18
2026-08-19	$6.35	$2,960,708,747	15 / 18
2026-08-20	$6.35	$2,960,708,747	15 / 18
2026-08-21	$6.39	$3,041,181,861	15 / 18
2026-08-22	$6.39	$3,041,181,861	15 / 18
2026-08-23	$6.39	$3,041,181,861	15 / 18
2026-08-24	$6.39	$3,041,181,861	15 / 18
2026-08-25	$6.49	$3,078,571,443	15 / 18
2026-08-26	$6.49	$3,078,571,443	15 / 18
2026-08-27	$6.49	$3,078,571,443	15 / 18
2026-08-28	$6.49	$3,078,571,443	15 / 18
2026-08-29	$6.49	$3,078,571,443	15 / 18
2026-08-30	$6.49	$3,078,571,443	15 / 18
2026-08-31	$6.49	$3,078,571,443	15 / 18
2026-09-01	$6.49	$3,078,571,443	15 / 18
2026-09-02	$6.49	$3,078,571,443	15 / 18
2026-09-03	$6.49	$3,078,571,443	15 / 18
2026-09-04	$6.49	$3,078,571,443	15 / 18
2026-09-05	$6.49	$3,078,571,443	15 / 18
2026-09-06	$6.49	$3,078,571,443	15 / 18
2026-09-07	$6.49	$3,078,571,443	15 / 18
2026-09-08	$6.49	$3,078,571,443	15 / 18
2026-09-09	$6.49	$3,078,571,443	15 / 18
2026-09-10	$6.49	$3,078,571,443	15 / 18
2026-09-11	$6.49	$3,078,571,443	15 / 18
2026-09-12	$6.49	$3,078,571,443	15 / 18
2026-09-13	$6.49	$3,078,571,443	15 / 18
2026-09-14	$6.49	$3,078,571,443	15 / 18
2026-09-15	$6.49	$3,078,571,443	15 / 18
2026-09-16	$6.49	$3,078,571,443	15 / 18
2026-09-17	$6.49	$3,078,571,443	15 / 18
2026-09-18	$6.49	$3,078,571,443	15 / 18
2026-09-19	$6.49	$3,078,571,443	15 / 18
2026-09-20	$6.49	$3,078,571,443	15 / 18
2026-09-21	$6.49	$3,078,571,443	15 / 18
2026-09-22	$6.49	$3,078,571,443	15 / 18
2026-09-23	$6.49	$3,078,571,443	15 / 18
2026-09-24	$6.49	$3,078,571,443	15 / 18
2026-09-25	$6.49	$3,078,571,443	15 / 18
2026-09-26	$6.49	$3,078,571,443	15 / 18
2026-09-27	$6.49	$3,078,571,443	15 / 18
2026-09-28	$6.49	$3,078,571,443	15 / 18
2026-09-29	$6.49	$3,078,571,443	15 / 18
2026-09-30	$6.48	$3,079,090,922	15 / 18
2026-10-01	$6.48	$3,079,090,922	15 / 18
2026-10-02	$6.48	$3,079,090,922	15 / 18
2026-10-03	$6.48	$3,079,090,922	15 / 18
2026-10-04	$6.48	$3,079,090,922	15 / 18
2026-10-05	$6.48	$3,079,090,922	15 / 18
2026-10-06	$6.48	$3,079,090,922	15 / 18
2026-10-07	$6.48	$3,079,090,922	15 / 18
2026-10-08	$6.48	$3,079,090,922	15 / 18
2026-10-09	$6.48	$3,079,090,922	15 / 18
2026-10-10	$6.48	$3,079,090,922	15 / 18
2026-10-11	$6.48	$3,079,090,922	15 / 18
2026-10-12	$6.48	$3,079,090,922	15 / 18
2026-10-13	$6.48	$3,079,090,922	15 / 18
2026-10-14	$6.48	$3,079,090,922	15 / 18
2026-10-15	$6.49	$3,082,954,559	15 / 18
2026-10-16	$6.49	$3,082,954,559	15 / 18
2026-10-17	$6.49	$3,082,954,559	15 / 18
2026-10-18	$6.49	$3,082,956,154	15 / 18
2026-10-19	$6.49	$3,082,956,154	15 / 18
2026-10-20	$6.49	$3,082,956,154	15 / 18
2026-10-21	$6.49	$3,082,956,154	15 / 18
2026-10-22	$6.49	$3,082,956,154	15 / 18
2026-10-23	$6.49	$3,082,956,154	15 / 18
2026-10-24	$6.49	$3,082,956,154	15 / 18

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold
2026-05-01	19	8
2026-06-01	18	8
2026-07-01	18	8
2026-08-01	19	8
2026-09-01	19	7
2026-10-01	19	8

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 19 Buy / Strong Buy · 8 Hold · 0 Sell / Strong Sell

0 upgrades0 downgrades1 maintains

Recent actions · Sep 25–Oct 24 · 1 recorded

Price-target changes

30 days

Individual price-target observations are unavailable.

0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

EPS between $0.44 and $0.46 in 2026-Q2Published status: Broken
GAAP gross margin of 73% in 2026-Q2Published status: Broken
Revenue between $355M and $365M in 2026-Q2Published status: Broken

Next proof point

Nov 3, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

3 of 4 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

3.4%Typical daily move · historical

Downside history

-48.3%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

Astera Labs, Inc. outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

This is a high-growth technology business whose thesis depends on AI fabric and switch products ramping successfully. Recent results support the thesis, but high risk and mixed progress on product expansion make execution important over the next 1 to 3 years.

What's priced into Astera Labs, Inc.

ALAB is expensive versus peers, with a 4.7-point premium, though the valuation measure has fallen from 40.7 to 28.2. The premium reflects optionality, or value tied to possible future opportunities, but confidence in that valuation measure is low, so the expectations gap is hard to assess precisely.

What the fundamentals likely do

Near-term results show strong growth: revenue rose 27% sequentially in Q2, and Q3 guidance calls for further growth. Gross margin is easing toward management’s 72% goal, while recent earnings beats and the low near-term miss assessment support the execution picture; a guidance cut remains a meaningful risk.

What Astera Labs, Inc. hinges on

Over the multi-year view, the thesis hinges on continued AI fabric and Scorpio X-Series growth, with margins staying near management’s stated range. Near-term expectations also depend on guidance, while rate cuts and strong results from major technology peers could support the sector backdrop.